Keyword: Imfinzi (durvalumab)
While a Keytruda-chemo combo showed significant improvement in cutting disease worsening or death in SCLC, it didn't extend patients' lives.
Lately, pharmas have been rebranding—more often than not, around oncology, rare diseases or both—and more could join the fold in 2020.
AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.
With the priority review, Imfinzi is now looking at a decision for use in frontline small cell lung cancer by the first quarter of 2020.
Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.
After watching from the sidelines as its rivals dove into I-O’s most coveted market, AstraZeneca finally has a win in previously untreated NSCLC.
Tagrisso, Lynparza and Imfinzi, as well as China, have teamed up for growth at AstraZeneca. But each faces its own fight just around the corner.
Roche’s Tecentriq is the only I-O drug approved in small cell lung cancer. But it may soon have to make some room for AstraZeneca’s Imfinzi.
AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.